Novavax, Inc. (NVAX) — closed signal from March 13, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 11, 2026 — -14.2% at the close.
Predicted vs. what happened
What happened
Reached 47% of the predicted growth at its peak, without hitting the target.
The thesis — published March 13, 2026
Novavax looks like a clearer, more reliable investment now because the business is actually getting healthier instead of just being a temporary vaccine trade. Unexpected profit and a licensing deal with Pfizer mean future revenue may feel more steady, more like regular royalties. Short-term regulation matters, but concrete news creates real near-term reasons the stock could re-rate.
Primary drivers
- Unexpected profit helped show real cash coming in
- Pfizer license could create steady royalty-like revenue
- The stock setup looks healthier and not overheated
- Adds healthcare exposure away from AI-focused names
How it played out
NVAX: target was not reached
Lyra published NVAX at $10.52 on 2026-03-13 with expected growth of 22%. The thesis pointed to an unexpected profit, a Pfizer license that could create steadier royalty-like revenue, a healthier stock setup, and healthcare exposure away from artificial-intelligence-focused names.
Inside the window from 2026-03-13 to 2026-06-11, NVAX peaked at $11.61 on 2026-05-27. That was a 10.3% gain, but it stayed below the $12.83 target. The stock ended at $9.03. The thesis partially played out on price strength, then missed the target and finished below the publication price.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.